Clinical trials: Margin, Tumor-Free
Adipocytic Neoplasm, Liposarcoma
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin…
- Conditions
- Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma
- Trial name
- NCT06239272
- Testing
- Surgical resection, Proton beam radiation therapy, Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 139 people
- Sponsor
- St. Jude Children's Research Hospital
Smoking, Lung Cancer
Centralized Lung Cancer EARly Detection Among Smokers (CLEAR Study)
This trial studies how well a centralized care strategy works in improving the quality of smoking cessation and shared decision making among patients who smoke and are considering lung cancer screening.
- Trial name
- NCT04200534
- Testing
- Best Practice, Nicotine Patch, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 358 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
HPV Positive Oropharyngeal Squamous Cell Carcinoma
ctDNA Liquid Biopsy for Early Assessment of Residual Disease in HPV-associated Head and Neck Cancer (Clear-HPVca)
The purpose of this study is to test a new liquid biopsy assay for detecting residual disease after surgery in patients with HPV-associated head and neck cancer.
- Trial name
- Clear-HPVca (NCT06730412)
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Kidney Cancer
DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE
RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900536
- Testing
- mutation analysis, polymorphism analysis, protein expression analysis
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with…
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05281471
- Testing
- olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- Where
- 33 sites in United States
- Volunteers
- 186 people
- Sponsor
- Genelux Corporation
Class III Malocclusion
Evaluating the Effectiveness of the Lower-Clear-Plate-Based Intermaxillary Traction
Patients at the Orthodontic Department of the University of Damascus Dental School will be examined, and subjects who meet the inclusion criteria will be included.
- Trial name
- NCT06596239
- Testing
- lower-clear-plate-based intermaxillary traction (LCP-IMT), Removable mandibular retractor (RMR)
- Where
- Syria
- Volunteers
- 30 people
- Sponsor
- Damascus University
Clear Cell Kidney Cancer, Kidney Cancer
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)
Kidney cancer belongs to a heterogeneous group of tumors and is the most common oncourological disease; up to 80% of cases are clear cell carcinoma.
- Conditions
- Clear Cell Kidney Cancer, Kidney Cancer, Kidney Cancer With PBRM1/BAP1/VHL/SETD2 Mutations
- Trial name
- NCT05941637
- Testing
- Axitinib 5 MG
- Sponsor
- Lynkcell Europe
White Spot Lesion of Tooth
Effect of Bioactive Resin Material Containing S-PRG Filler on White Spot Lesions
the effect of bioactive resin composite containing S-PRG filler will be tested as the material of choice for attachments bonded on teeth prior to the use of orthodontic clear aligners compared to the conventionally used flowable…
- Trial name
- NCT07715942
- Testing
- Bioactive resin composite containing S-PRG filler, Conventional flowable composite is used for the attachments for the clear orthodontic aligners
- Where
- Jordan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Jordan University of Science and Technology
Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
This is a Phase II Clinical Trial that will evaluate the use of adaptive dosing of pembro-axi in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
- Trial name
- NCT06860386
- Testing
- Pembrolizumab, Axitinib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0)…
- Conditions
- Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy
- Trial name
- NCT07389629
- Testing
- QL1706 Combined With Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Clear Cell Renal Cell Carcinoma
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT05199272
- Testing
- 23ME-00610
- Where
- 13 sites in United States, Canada
- Volunteers
- 141 people
- Sponsor
- 23andMe, Inc.
Solid Tumor
A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma
The safety and tolerability of CVX-060 have been established in the first-in-human clinical trial, CVX-060-101. Thus, this phase Ib/II trial is to assess the safety and pharmacokinetics (PK) profiles of combining CVX-060 with…
- Trial name
- NCT00982657
- Testing
- CVX-060 + sunitinib, Sunitinib
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Pfizer
Peripheral Nerve Blocks
Computer Assisted Instrument Guidance (CAIG) for Orthopedic Peripheral Nerve Blocks
The objective of this research is to determine if the addition of the Clear Guide ONE, a Computer Assisted Instrument Guidance (CAIG) system, provides improvement over existing ultrasound guided, needle-based procedures for…
- Trial name
- NCT02614222
- Testing
- Peripheral Nerve Blocks with CAIG
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Clear Guide Medical
Cataract
Comparison of Wound Integrity for Clear Corneal Cataract Incisions
This is a randomized controlled trial to evaluate the safety and efficacy of two different closing methods for clear corneal cataract incisions
- Trial name
- NCT05242653
- Testing
- pressure by a cotton swab, stromal hydration with the balanced salt solution（BSS）
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Clear-cell Metastatic Renal Cell Carcinoma
A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
A-PREDICT is a study of axitinib in patients with metastatic renal cell carcinoma unsuitable for nephrectomy (as judged by the treating clinician) to evaluate efficacy, safety, toxicity and changes in biomarkers during therapy.
- Trial name
- A-PREDICT (NCT01693822)
- Testing
- Axitinib
- Where
- 11 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Narrow Palate
Comparison of the Predictability of Dentoalveolar Expansion With Two Clear Aligner Systems
To analyze the clinical predictability of transverse arch expansion achieved with two clear aligner systems (Invisalign, Angel Aligner-Angel Aligner Pro) by comparing planned and achieved dental movements through digital model…
- Trial name
- NCT07608302
- Testing
- Invisalign expansion, Angel Aligner, Angel Aligner Pro
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- University of Salamanca
Clear Cell Renal Cell Carcinoma
Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma
The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in participants diagnosed with advanced renal cell carcinoma.
- Trial name
- NCT02667886
- Testing
- X4P-001, axitinib
- Where
- 20 sites in United States, South Korea
- Volunteers
- 74 people
- Sponsor
- X4 Pharmaceuticals
Urothelial Bladder Cancer, Gastric Adenocarcinoma
Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
Treatment will consist of a PARP inhibitor (niraparib) monotherapy priming period (cycle 0; 21 days); an anti-PD-1 antibody (Dostarlimab ; TSR-042) will then be added from C1D1 every 21 days in combination for the first 4 cycles…
- Conditions
- Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma, Head and Neck Cancer
- Trial name
- NIRADO (NCT04779151)
- Testing
- Dostarlimab, Niraparib
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
This phase I trial studies the side effects and best dose of activated T-cell therapy when given together with low-dose aldesleukin and sargramostim in treating patients with ovarian, fallopian tube, or primary peritoneal cancer…
- Conditions
- Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02470559
- Testing
- Aldesleukin, HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis
- Sponsor
- Barbara Ann Karmanos Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.